@article{fdi:010053644,
  title = {{I}n vitro antiviral activity of arbidol against {C}hikungunya virus and characteristics of a selected resistant mutant},
  author = {{D}elogu, {I}. and {P}astorino, {B}. and {B}aronti, {C}{\'e}cile and {N}ougair{\`e}de, {A}. and {B}onnet, {E}. and de {L}amballerie, {X}avier},
  editor = {},
  language = {{ENG}},
  abstract = {{A}rbidol ({ARB}) is an antiviral drug originally licensed in {R}ussia for use against influenza and other respiratory viral infections. {A}lthough a broad-spectrum antiviral activity has been reported for this drug, there is until now no data regarding its effects against alphavirus infection. {H}ere, the in vitro antiviral effect of {ARB} on {C}hikungunya virus ({CHIKV}) replication was investigated and this compound was found to present potent inhibitory activity against the virus propagated onto immortalized {V}ero cells or primary human fibroblasts ({MRC}-5 lung cells) ({IC}50 < 10 mu g/ml). {A} {CHIKV} resistant mutant was then selected and adapted to growth in the presence of 30 mu g/ml {ARB} in {MRC}5 cells; its complete sequence analysis revealed a single amino acid substitution ({G}407{R}) localized in the {E}2 envelope protein. {T}o confirm the {G}407{R} role in the molecular mechanism of {ARB} resistance, a {CHIKV} infectious clone harboring the same substitution was engineered, tested, and was found to display a similar level of resistance. {F}inally, our results demonstrated the effective in vitro antiviral activity of {ARB} against {CHIKV} and gave some tracks to understand the molecular basis of {ARB} activity.},
  keywords = {{C}hikungunya virus ; {A}rbidol ; {A}ntiviral ; {A}lphavirus ; {A}rbidol resistance ; {M}utant},
  booktitle = {},
  journal = {{A}ntiviral {R}esearch},
  volume = {90},
  numero = {3},
  pages = {99--107},
  ISSN = {0166-3542},
  year = {2011},
  DOI = {10.1016/j.antiviral.2011.03.182},
  URL = {https://www.documentation.ird.fr/hor/fdi:010053644},
}